메뉴 건너뛰기




Volumn 21, Issue 3, 2014, Pages 170-177

A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting

Author keywords

capecitabine; Eribulin; gemcitabine; metastatic breast cancer; toxicity; vinorelbine

Indexed keywords

ANTIANEMIC AGENT; ANTIEMETIC AGENT; BEVACIZUMAB; CAPECITABINE; CREATININE; ERIBULIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; NAVELBINE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FURAN DERIVATIVE; KETONE; VINBLASTINE;

EID: 84930422579     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214525369     Document Type: Article
Times cited : (14)

References (8)
  • 3
    • 77954335786 scopus 로고    scopus 로고
    • Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up
    • Cardoso F, Senkus-Konefka E, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol. 2010 ; 21 (supppl 5). 15-19
    • (2010) Ann Oncol , vol.21 , pp. 15-19
    • Cardoso, F.1    Senkus-Konefka, E.2    Fallowfield, L.3
  • 4
    • 18444417397 scopus 로고    scopus 로고
    • Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
    • Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer. 2002 ; 86: 1367-1372
    • (2002) Br J Cancer , vol.86 , pp. 1367-1372
    • Talbot, D.C.1    Moiseyenko, V.2    Van Belle, S.3
  • 5
    • 79952487463 scopus 로고    scopus 로고
    • Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
    • Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 ; 377: 914-923
    • (2011) Lancet , vol.377 , pp. 914-923
    • Cortes, J.1    O'Shaughnessy, J.2    Loesch, D.3
  • 6
    • 84863278868 scopus 로고    scopus 로고
    • Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial
    • Donoghue M, Lemery SJ, Yuan W, et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial. Clin Cancer Res. 2012 ; 18: 1496-1505
    • (2012) Clin Cancer Res , vol.18 , pp. 1496-1505
    • Donoghue, M.1    Lemery, S.J.2    Yuan, W.3
  • 7
    • 0023092594 scopus 로고
    • A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
    • Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987 ; 40: 373-383
    • (1987) J Chronic Dis , vol.40 , pp. 373-383
    • Charlson, M.E.1    Pompei, P.2    Ales, K.L.3
  • 8
    • 77949321968 scopus 로고    scopus 로고
    • Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
    • Saad ED, Katz A, Hoff PM, et al. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol. 2010 ; 21: 7-12
    • (2010) Ann Oncol , vol.21 , pp. 7-12
    • Saad, E.D.1    Katz, A.2    Hoff, P.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.